RCMI Coordinating Center (RCMI CC) Header Logo

Connection

Elaine Nguyen to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Elaine Nguyen has written about Cost-Benefit Analysis.
Elaine Nguyen
Connection Strength
1.269
Cost-Benefit Analysis
  1. Nguyen E, Coleman CI, Kohn CG, Weeda ER. Ranolazine in patients with type 2 diabetes and chronic angina: A cost-effectiveness analysis and assessment of health-related quality-of-life. Int J Cardiol. 2018 Dec 15; 273:34-38.
    View in: PubMed
    Score: 0.610
  2. Nguyen E, Egri F, Mearns ES, White CM, Coleman CI. Cost-Effectiveness of High-Dose Edoxaban Compared with Adjusted-Dose Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation Patients. Pharmacotherapy. 2016 May; 36(5):488-95.
    View in: PubMed
    Score: 0.516
  3. Nguyen E, Coleman CI, Nair S, Weeda ER. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk. J Diabetes Complications. 2018 02; 32(2):210-215.
    View in: PubMed
    Score: 0.143
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support